MRK · News · 20260923N

Clinical Pipeline Developments

Merck & Co., Inc. · 2026-09-23 · Importance 23 · Surprise 24 · In source text

Bank of America maintained a Buy rating and expects Merck’s shares could be re-rated as clinical catalysts emerge over the next 12 to 18 months. Key catalysts include Phase 3 SAC-TMT data in lung cancer and data for intismeran, Merck’s personalized cancer-vaccine collaboration with Moderna, in renal cell carcinoma and bladder cancer. Additional potential catalysts include Merck’s TL1a program and ophthalmology pipeline, with some data expected at the European Society for Medical Oncology meeting.

Key facts

• Key focus areas for Merck include SAC-TMT data in lung cancer and the personalized cancer vaccine intismeran developed with Moderna, with upcoming data in renal cell carcinoma and bladder cancer. source
• Merck has a Phase 3 SAC-TMT trial in lung cancer with results identified as a key trial. source
• Merck's personalized cancer vaccine intismeran is developed with Moderna and is expected to have data presented at the European Society for Medical Oncology meeting. source
• Merck's TL1a program and ophthalmology pipeline are highlighted as important future catalysts. source
• Merck has upcoming abstracts for the ESMO conference. source
• Bank of America has maintained its 'buy' rating for Merck & Co Inc, anticipating a potential re-rating of its shares due to several clinical catalysts in its oncology and broader pipeline over the next 12 to 18 months. source

Impact estimates